18F-flortaucipir uptake patterns in clinical subtypes of primary progressive aphasia

Neurobiol Aging. 2019 Mar:75:187-197. doi: 10.1016/j.neurobiolaging.2018.11.017. Epub 2018 Nov 23.

Abstract

We analyzed 18F-flortaucipir uptake patterns and structural changes in patients with subtypes of primary progressive aphasia (PPA) using 18F-flortaucipir positron emission tomography and volumetric magnetic resonance imaging. We enrolled 34 consecutive patients with PPA (10 nonfluent/agrammatic PPA [nfvPPA], 18 semantic variant PPA [svPPA], and 6 logopenic variant PPA [lvPPA], as well as 20 healthy controls, and 20 patients with Alzheimer's disease. 18F-flortaucipir uptake was increased in the frontal cortex and underlying white matter, and subcortical nuclei in the 10 nfvPPA and 8 nfvPPA-amyloid-β (Aβ)- subgroup patients. In the svPPA patients (both the 13 svPPA-Aβ- and 5 svPPA-Aβ+), uptake generally increased in the widespread neocortex with left anterior temporal predominance. 18F-flortaucipir uptake patterns in the 6 lvPPA and the 5 lvPPA-Aβ+ subgroup patients were similar to those seen in the patients with Alzheimer's disease with mild predominance in the left lateral temporal cortex. Cortical thinning in each PPA subtype corresponded with increased 18F-flortaucipir uptake. 18F-flortaucipir uptake patterns and cortical atrophy were distinct and corresponded to areas related to the specific language functions that are impaired in each subtype of PPA.

Keywords: (18)F-flortaucipir; Positron emission tomography; Primary progressive aphasia; Tau.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / diagnosis
  • Alzheimer Disease / pathology*
  • Amyloid / metabolism
  • Aphasia, Primary Progressive / diagnosis
  • Aphasia, Primary Progressive / pathology*
  • Atrophy / pathology
  • Carbolines / pharmacology*
  • Female
  • Humans
  • Language
  • Male
  • Positron-Emission Tomography / methods
  • White Matter / pathology

Substances

  • Amyloid
  • Carbolines
  • 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole